KZR | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 2%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.27%

1 Month

13.42%

3 Months

17.07%

6 Months

18.02%

1 Year

53.05%

2 Year

807.16%

Key data

Stock price

$7.27

P/E Ratio

N/A

DAY RANGE

$7.25 - $7.34

EPS

-$7.66

52 WEEK RANGE

$3.53 - $7.55

52 WEEK CHANGE

$54.68

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

7.372 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.15

PUBLIC FLOAT

AVERAGE 10 VOLUME

$144,052

AVERAGE 30 VOLUME

$141,975

Company detail

CEO: John Fowler
Region: US
Website: kezarlifesciences.com
Employees: 60
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Kezar Life Sciences, Inc. engages in the discovery and development of novel small molecule therapeutics. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis.

KZR - Kezar Life Sciences, Inc.